RELAPSED/REFRACTORY MULTIPLE MYELOMA

This study tests a new drug, cemsidomide, combined with dexamethasone in people with multiple myeloma that has returned or not responded to at least three prior treatments. About 100 adults will receive the drug combo to see if it shrinks tumors and how safe it is. The goal is to…

This study tests a new treatment called AZD0120, which uses a patient's own immune cells engineered to attack two targets (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has returned or stopped responding to prior treatments. The study compares AZD0120 t…

This early-phase study tests a new drug called RO7851624 in 160 people with relapsed/refractory multiple myeloma who have tried several standard treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the dr…

This study tests a new treatment called AZD0120 for people with multiple myeloma that has come back or stopped responding to at least three prior therapies. AZD0120 is a personalized cell therapy that reprograms a patient's own immune cells to attack two targets on myeloma cells …

This study tests a new experimental drug, REGN7945, combined with another experimental drug, linvoseltamab, in people with multiple myeloma that has returned or not responded to at least three prior treatments. The goal is to see if the combination is safe and can shrink tumors b…

This study tests whether giving the drug belantamab mafodotin less often, combined with other standard cancer medicines, can still control multiple myeloma while reducing side effects like eye problems. About 200 adults whose cancer has returned or stopped responding to prior tre…

This early-phase trial tests whether high-dose vitamin C, combined with a lower dose of the chemotherapy drug melphalan and a stem cell transplant, is safe and effective for people with relapsed multiple myeloma. The study enrolls 18 adults who have already tried at least three p…

This early-stage study tests a new drug, PF-07994525, in about 120 adults with advanced multiple myeloma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. The study has two parts:…

This early-stage trial tests a new type of immunotherapy called CAR T-cells, which are made from a patient's own immune cells and engineered to recognize and attack a protein called KMA on myeloma cells. The study will enroll 12 adults with relapsed or refractory multiple myeloma…

This study tests a new drug called sonrotoclax, alone or with other medicines, in people with a type of multiple myeloma that has come back or stopped responding to treatment. The trial includes 246 participants and aims to find the safest and most effective dose. Researchers wil…

This study tests a new type of CAR-T cell therapy, boosted with IL-15, in 25 people with multiple myeloma or plasma cell leukemia that has come back or not responded to treatment. The therapy uses the patient's own immune cells, engineered to target cancer cells. The goal is to s…

This early-phase trial is testing a new treatment called IMV102 for people with relapsed/refractory multiple myeloma, a type of blood cancer that has not responded to at least three prior therapies. IMV102 is a personalized therapy made from the patient's own immune cells (CAR-T …

This early-stage study tests a new drug called ISB 2001 in people with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to check the drug's safety and how well it fights the cancer. About 200 participants will receive the drug in…

This early-stage study tests a new antibody drug (SAR446523) given as a shot under the skin for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. The study has two parts: first, finding the safest and most effective dose, the…

This study tests two drugs, elranatamab and isatuximab, given as shots under the skin for people with multiple myeloma that has returned or not responded to at least two prior treatments. The goal is to see if the combination can shrink tumors and control the disease. About 30 pa…

This study tests an experimental drug called LBL-034 in people whose multiple myeloma has returned or no longer responds to standard treatments. The trial has two phases: first, finding the safest dose, and then checking how well the drug shrinks tumors. About 342 adults will tak…

This early-phase study tests a new treatment called CT0596 CAR-T cells for people with multiple myeloma or plasma cell leukemia that has come back or not responded to standard therapies. The main goals are to check safety, find the best dose, and see how well it controls the canc…

This early-stage study tests a new treatment called CB-011 for people with multiple myeloma that has returned or stopped responding to other therapies. CB-011 uses CRISPR gene editing to create donor immune cells that target and attack cancer cells. The study aims to find the saf…

This study follows about 300 people with multiple myeloma that has come back or stopped responding to treatment. Researchers will watch how well standard treatments work in real-life settings over 24 months, focusing on response rates, safety, and how patients feel. The goal is t…